NCT03946345 (HERO) is a clinical trial of Iohexol Inj 300 MG/ML in Acute Kidney Injury, sponsored by Radboud University Medical Center.

Who is sponsoring NCT03946345?

NCT03946345 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT03946345?

Interventions in NCT03946345: Iohexol Inj 300 MG/ML.

What condition does NCT03946345 study?

NCT03946345 studies Acute Kidney Injury, Critically Ill Children.

Is NCT03946345 still recruiting?

NCT03946345 is currently status unknown. Last updated 10 May 2019.

Last reviewed 2019-05-10 · How we verify

NCT03946345: HERO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iohexol for Measuring Renal Function

Status unknown Last updated 10 May 2019

What this trial tests

trial testing Iohexol Inj 300 MG/ML in Acute Kidney Injury in 105 participants. Status unknown.

Timeline

1 May 2019

Primary endpoint
30 April 2021

30 April 2021

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	105
Start date	1 May 2019
Primary completion	30 April 2021
Estimated completion	30 April 2021
Sites	1 location across Netherlands

Drugs / interventions tested

Iohexol Inj 300 MG/ML — full drug profile →

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →
Critically Ill Children — all drugs for Critically Ill Children →

Sponsor

Radboud University Medical Center

Who can join

Under 18, any sex, with Acute Kidney Injury or Critically Ill Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 25-35% of all children admitted to the paediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) will develop Acute Kidney Injury (AKI) during the first seven days after admission. AKI is associated with a worse outcome, including an increased risk of mortality compared to patients without AKI. However, this AKI prevalence estimation is based on serum creatinine based glomerular filtration rate (eGFR), which is known to be inaccurate. The investigators postulate that measured GFR (mGFR) based on iohexol clearance in critically ill children will detect a higher prevalence of children with AKI than currently used methods based on endogenous markers. This study will additionally provide mechanistic knowledge on the relative contribution of GFR and renal transport to renal function in critically ill children.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Glomerular filtration rate in critically ill neonates and children: creatinine-based estimations versus iohexol-based measurements.
Smeets NJL, Teunissen EMM, van der Velden K, van der Burgh MJP, et al · · 2023 · cited 12× · PMID 35916956 · DOI 10.1007/s00467-022-05651-w

Verify or expand the search:

Other trials of Iohexol Inj 300 MG/ML

Trials testing the same drug.

NCT05008276 — Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study) · recruiting
NCT03769597 — Description of the Evolution of Plasma and Urinary Concentrations of Iohexol in a Cirrhotic Patient Population · Phase 4 · completed
NCT03584217 — Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study · Phase 1, PHASE2 · unknown

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03946345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 10 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03946345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing